Best Oligonucleotide / ASO CDMOs in Japan

Synthesis scale

Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile.

Chemistry & conjugation

Confirm experience with your backbone and modifications (phosphorothioate, 2'-MOE/F) and any conjugation (GalNAc, lipid) your molecule requires.

Purity & analytics

Full-length product, deletion/addition impurities, and residual metals drive release. Look for established orthogonal analytics.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Japan operates one of the most developed advanced-therapy regulatory frameworks globally, distinguishing between three product classes with tailored requirements: regenerative medical products, cellular/tissue-based products, and gene therapy products. The framework's conditional and time-limited early approval pathway (introduced 2014, revised 2024) has accelerated advanced-therapy commercialization in Japan compared to most other markets. For CDMOs, this means Japanese advanced-therapy manufacturers have accumulated real experience with regulatory-supported early commercial supply — a signal that materially differs from the more restrictive US and EU pathways. Cross-reference with cell therapy, AAV, and cell & gene therapy umbrella pages for Japanese CDMO capability at the modality level.

PMDA GMP is generally regarded as tier-equivalent to FDA and EMA — inspections are rigorous, the framework is well-documented, and PMDA participates in the PIC/S mutual-recognition framework alongside EMA and other major regulators. For Japanese-manufactured product supplying US or EU markets, the qualifying signal is FDA or EMA inspection posture on the specific facility (not just PMDA certification), because FDA and EMA conduct their own facility inspections regardless of PMDA status. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly. Japanese CDMOs supplying global markets typically hold cross-jurisdictional certification.

The Japanese CDMOs with US and EU inspection posture typically operate global site networks or maintain FDA-inspected export facilities. Cross-check with the US region ranking and Europe region ranking to identify Japanese CDMOs appearing across regions — these have demonstrated multi-jurisdictional inspection posture. Individual profile pages surface facility-level detail on which specific Japanese sites carry which regulatory certifications.

Who are the top Oligonucleotide / ASO CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Oligonucleotide / ASO CDMOs include Ajinomoto Bio-Pharma Services, Sumitomo Chemical Advanced Medical. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Oligonucleotide / ASO CDMOs have FDA inspection records?

CDMO Signal tracks 0 Oligonucleotide / ASO CDMOs with FDA inspection records and 1 EMA/MHRA GMP certificate across the group.

What should I look for in an oligonucleotide CDMO?

Match synthesis scale to your demand, confirm experience with your backbone chemistry and any conjugation (e.g. GalNAc), prioritize strong purity analytics, and a clean FDA and EMA/MHRA record.

What therapeutics do oligonucleotide CDMOs make?

Antisense oligonucleotides (ASOs), siRNAs, aptamers, and related nucleic-acid drugs — increasingly with conjugation chemistries like GalNAc for targeted delivery.